An election night bereft of answers quells biopharma's 'worst-case' fears — analysts
What to make of an election night that gave the country a deluge of nerves and no final answers? Well, if you’re a biotech or a pharma executive or investor, you might decide that you got the best of both worlds, analysts suggested Wednesday morning.
Although results are still quite up in the air as of Wednesday morning, by most forecasts, the presidency remained a tossup, while Republicans appear narrow favorites to maintain control of the Senate and Democrats have maintained control of the House. That’s a recipe for a divided government, one unlikely to pass the kind of drug pricing legislation that has gained traction on both parties, SVB Leerink’s Geoffrey Porges wrote.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,300+ biopharma pros reading Endpoints daily — and it's free.